Armata Pharmaceuticals – BioScience Managers

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

2nd October 2023/in Armata Pharmaceuticals

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of Defense LOS ANGELES, Sept. 26, 2023 /Link here/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for […]

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

28th September 2023/in Armata Pharmaceuticals, Uncategorised

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of Defense LOS ANGELES, /Link Here/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and […]

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

12th August 2022/in Armata Pharmaceuticals

MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

24th May 2022/in Armata Pharmaceuticals, Uncategorised

Link to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]

Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

8th March 2022/in Armata Pharmaceuticals, BioSciences Managers

Link to full article Feb. 22, 2022 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared Armata’s Investigational New Drug (IND) application to initiate a clinical trial of […]

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

8th March 2022/in Armata Pharmaceuticals, BioSciences Managers

Link to full article Feb. 9, 2022 Armata intends to use the net proceeds from this transaction to advance its clinical pipeline and strengthen its bacteriophage platform. The clinical pipeline is led by AP-PA02, currently under evaluation in the ‘SWARM-P.a.‘ trial as a novel therapeutic to treat chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. A […]

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

8th March 2022/in Armata Pharmaceuticals, BioSciences Managers

Link to full article Enhanced AP-PA02 enters SWARM-P.a. study AP-PA02 identified as lead cocktail for non-cystic fibrosis bronchiectasis Phase 2 trial Distinct phage cocktail (AP-PA03) for pneumonia advances to manufacturing Jan. 5, 2022 The improvements in AP-PA02 reflect Armata’s core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. Prior to […]

Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs

8th March 2022/in Armata Pharmaceuticals, BioSciences Managers

Link to full article Nov. 18, 2021 Announces FDA clearance of IND to initiate Phase 1b/2a clinical trial of AP-SA02 in Staphylococcus aureus bacteremia (“diSArm” Study) Achieves significant milestone under previously announced therapeutic development award from the Cystic Fibrosis Foundation for continued advancement of Phase 1b/2a SWARM-P.a. clinical trial of AP-PA02 in Pseudomonas aeruginosa infections […]

Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals

8th March 2022/in Armata Pharmaceuticals, Uncategorised

Link to full article Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomonas aeruginosa respiratory infections in CF patients Innoviva, a significant Armata shareholder, also elected to participate Oct. 28, 2021 In accordance with the terms of the investment agreement, […]

Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

12th August 2021/in Armata Pharmaceuticals

Link to Full Article Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa Announced that Todd R. Patrick, CEO, has retired from the Company. Brian Varnum, PhD, former President and Chief Development Officer, has been appointed the Company’s new CEO MARINA DEL REY, […]